- Home
- NRO vs ACRS Comparison
NRO vs ACRS Comparison
Compare NRO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- ACRS
- Stock Information
- Founded
- NRO 2003
- ACRS 2012
- Country
- NRO United States
- ACRS United States
- Employees
- NRO N/A
- ACRS N/A
- Industry
- NRO Finance/Investors Services
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- ACRS Health Care
- Exchange
- NRO Nasdaq
- ACRS Nasdaq
- Market Cap
- NRO 156.7M
- ACRS 165.7M
- IPO Year
- NRO N/A
- ACRS 2015
- Fundamental
- Price
- NRO $3.27
- ACRS $1.43
- Analyst Decision
- NRO
- ACRS Strong Buy
- Analyst Count
- NRO 0
- ACRS 8
- Target Price
- NRO N/A
- ACRS $9.71
- AVG Volume (30 Days)
- NRO 239.4K
- ACRS 1.3M
- Earning Date
- NRO 01-01-0001
- ACRS 08-06-2025
- Dividend Yield
- NRO 11.41%
- ACRS N/A
- EPS Growth
- NRO N/A
- ACRS N/A
- EPS
- NRO N/A
- ACRS N/A
- Revenue
- NRO N/A
- ACRS $17,777,000.00
- Revenue This Year
- NRO N/A
- ACRS N/A
- Revenue Next Year
- NRO N/A
- ACRS $11.77
- P/E Ratio
- NRO N/A
- ACRS N/A
- Revenue Growth
- NRO N/A
- ACRS N/A
- 52 Week Low
- NRO $2.51
- ACRS $1.05
- 52 Week High
- NRO $3.45
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NRO 55.93
- ACRS 51.06
- Support Level
- NRO $3.19
- ACRS $1.38
- Resistance Level
- NRO $3.27
- ACRS $1.52
- Average True Range (ATR)
- NRO 0.04
- ACRS 0.10
- MACD
- NRO 0.00
- ACRS -0.01
- Stochastic Oscillator
- NRO 86.08
- ACRS 39.10
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.